Pharmaceutical

CMN-005 by CoImmune for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval

CMN-005 is under clinical development by CoImmune and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma.

Sep 10, 2024 - 04:00
CMN-005 is under clinical development by CoImmune and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma.
Read the original article

Tags:

Previous Article

CMN-005 by CoImmune for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associa...

Next Article

CMN-005 by CoImmune for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Protesters slam health insurance lobby for Medicare Advantage coverage restrictions

STAT+: Protesters slam health insurance lobby for Medic...

Jun 28, 2023

Ransomware attack shuts down hospital emergency rooms in several states

Ransomware attack shuts down hospital emergency rooms i...

Aug 9, 2023

STAT+: STAT-Harris Poll: Nearly half of U.S. adults would spend $100 a month for Ozempic, other weight loss drugs

STAT+: STAT-Harris Poll: Nearly half of U.S. adults wou...

Jun 26, 2023